Short-term outcomes of endoscopic resection for colorectal neuroendocrine tumors: Japanese multicenter prospective C-NET STUDY
- PMID: 37986226
- DOI: 10.1111/den.14728
Short-term outcomes of endoscopic resection for colorectal neuroendocrine tumors: Japanese multicenter prospective C-NET STUDY
Abstract
Objectives: The incidence of colorectal neuroendocrine tumors (NETs) has increased with colorectal cancer screening programs and increased colonoscopies. The management of colorectal NETs has recently shifted from radical surgery to endoscopic resection. We aimed to evaluate the short-term outcomes of various methods of endoscopic resection for colorectal NETs.
Methods: Among those registered in the C-NET STUDY, patients with colorectal NETs who underwent endoscopic treatment as the initial therapy were included. Short-term outcomes, such as the en bloc resection rate and R0 resection (en bloc resection with tumor-free margin) rate, were analyzed based on treatment modalities.
Results: A total of 472 patients with 477 colorectal NETs received endoscopic treatment. Of these, 418 patients with 421 lesions who met the eligibility criteria were included in the analysis. The median age of the patients was 55 years, and 56.9% of them were men. The lower rectum was the most commonly affected site (88.6%), and lesions <10 mm accounted for 87% of the cases. Endoscopic submucosal resection with a ligation device (ESMR-L, 56.5%) was the most common method, followed by endoscopic submucosal dissection (ESD, 31.4%) and endoscopic mucosal resection using a cap (EMR-C, 8.5%). R0 resection rates <10 mm were 95.5%, 94.8%, and 94.3% for ESMR-L, ESD, and EMR-C, respectively. All 16 (3.8%) patients who developed treatment-related complications could be treated conservatively. Overall, 23 (5.5%) patients had incomplete resection without independent clinicopathological risk factors.
Conclusion: ESMR-L, ESD, and EMR-C were equally effective and safe for colorectal NETs with a diameter <10 mm.
Keywords: colonoscopy; colorectal neuroendocrine tumor; endoscopic mucosal resection; endoscopic submucosal dissection.
© 2023 Japan Gastroenterological Endoscopy Society.
Similar articles
-
Efficacy of endoscopic submucosal resection with a ligation device for small rectal neuroendocrine tumor: study protocol of a multicenter open-label randomized control trial (BANDIT trial).BMC Gastroenterol. 2024 Feb 8;24(1):69. doi: 10.1186/s12876-024-03130-0. BMC Gastroenterol. 2024. PMID: 38331727 Free PMC article.
-
Optimization of Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection Strategies for Rectal Neuroendocrine Tumors Within 20 mm.Am Surg. 2024 Jun;90(6):1176-1186. doi: 10.1177/00031348241226722. Epub 2024 Jan 8. Am Surg. 2024. PMID: 38192125
-
Endoscopic submucosal resection using a ligation device without injection for duodenal neuroendocrine tumors.Surg Endosc. 2019 Jun;33(6):2008-2014. doi: 10.1007/s00464-018-06642-5. Epub 2019 Jan 2. Surg Endosc. 2019. PMID: 30604268
-
Colorectal endoscopic submucosal dissection: Technical advantages compared to endoscopic mucosal resection and minimally invasive surgery.Dig Endosc. 2014 Jan;26 Suppl 1:52-61. doi: 10.1111/den.12196. Epub 2013 Nov 5. Dig Endosc. 2014. PMID: 24191896 Review.
-
Endoscopic mucosal resection and endoscopic submucosal dissection: technique and new directions.Curr Opin Gastroenterol. 2017 Sep;33(5):315-319. doi: 10.1097/MOG.0000000000000388. Curr Opin Gastroenterol. 2017. PMID: 28704212 Review.
Cited by
-
Efficacy of endoscopic intermuscular dissection vs. endoscopic submucosal dissection in treating rectal neuroendocrine tumors < 10 mm.Endosc Int Open. 2025 Aug 6;13:a26415725. doi: 10.1055/a-2641-5725. eCollection 2025. Endosc Int Open. 2025. PMID: 40860702 Free PMC article.
-
Optimal endoscopic resection method based on vertical margin distance for small rectal neuroendocrine tumors: Propensity score-matched study.Endosc Int Open. 2025 Aug 15;13:a26551320. doi: 10.1055/a-2655-1320. eCollection 2025. Endosc Int Open. 2025. PMID: 40860711 Free PMC article.
-
Factors Influencing Resection Time in Endoscopic Submucosal Dissection for Rectal Neuroendocrine Tumors.DEN Open. 2025 Sep 2;6(1):e70199. doi: 10.1002/deo2.70199. eCollection 2026 Apr. DEN Open. 2025. PMID: 40909210 Free PMC article.
-
Current status of endoscopic resection for small rectal neuroendocrine tumors.World J Gastroenterol. 2025 May 21;31(19):106814. doi: 10.3748/wjg.v31.i19.106814. World J Gastroenterol. 2025. PMID: 40497093 Free PMC article. Review.
References
REFERENCES
-
- Modlin IM, Lye KD, Kidd M. A 5‐decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934–959.
-
- Ito T, Igarashi H, Nakamura K et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: A nationwide survey analysis. J Gastroenterol 2015; 50: 58–64.
-
- Sekiguchi M, Sekine S, Sakamoto T et al. Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion. J Gastroenterol 2015; 50: 1184–1189.
-
- Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 2008; 113: 2655–2664.
-
- Basuroy R, O'Donnell CM, Srirajaskanthan R, Ramage JK. Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme. Colorectal Dis 2018; 20: O85–O91.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous